Taho Pharmaceuticals Ltd.

Taho Pharmaceuticals Ltd. is a Taiwan-based pharmaceutical company specializing in innovative drug delivery technologies, with a primary focus on transdermal patches and transmucosal oral dissolving films. Established in 2010 and headquartered in Taipei, Taho aims to enhance the clinical performance and accessibility of established pharmaceutical compounds by reengineering them into novel dosage forms that improve patient compliance, safety, and therapeutic efficacy. The company’s proprietary platforms, such as the Transepithelial Delivery System, enable the delivery of drugs through the skin or mucosal membranes, offering benefits like consistent plasma levels and reduced risk of choking—especially valuable for populations with swallowing difficulties. Taho’s development pipeline targets central nervous system, geriatric, and pediatric disorders, including products for chemotherapy-induced nausea, anticoagulation therapy, ADHD, epilepsy, and opioid addiction. Some of its products have reached major international markets, signifying its role as a bridge between innovative drug delivery and unmet medical needs in both regional and global pharmaceutical sectors.